Stratos Wealth Partners’s First Trust Nasdaq Pharmaceuticals ETF FTXH Stock Holding History

Stratos Wealth Partners’s Portfolio FTXH Stock Details FTXH Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$312K	Buy	8,180 +696	+9%	+$24.2K	﹤0.01%	1384
2026 Q1	$257K	Sell	7,484 -150	-2%	-$5.13K	﹤0.01%	1408
2025 Q4	$251K	Sell	7,634 -428	-5%	-$13.3K	﹤0.01%	1388
2025 Q3	$230K	Buy	+8,062	New	+$219K	﹤0.01%	1390
2024 Q3	–	Sell	-8,361	Closed	-$228K	–	1475
2024 Q2	$228K	Sell	8,361 -822	-9%	-$22K	﹤0.01%	1216
2024 Q1	$257K	Buy	+9,183	New	+$253K	﹤0.01%	1165
2018 Q4	–	Sell	-501	Closed	-$12K	–	1441
2018 Q3	$12K	Buy	+501	New	+$11.6K	﹤0.01%	2088

Other funds holding FTXH

LPL Financial San Diego, California $445B AUM 25.58% 1-Year Est. Return

Oppenheimer & Co New York $9.37B AUM 36.4% 1-Year Est. Return

Raymond James Financial St Petersburg, Florida $369B AUM 28.27% 1-Year Est. Return

Truist Financial Charlotte, North Carolina $83.7B AUM 27.22% 1-Year Est. Return

MIM

Marshall Investment Management Littleton, Colorado $241M AUM 30.53% 1-Year Est. Return

AIP

Ameritas Investment Partners Lincoln, Nebraska $3.75B AUM 46.53% 1-Year Est. Return

Cambridge Investment Research Advisors Fairfield, Iowa $44.6B AUM 28.94% 1-Year Est. Return

Nilsine Partners Greenwood Village, Colorado $1.45B AUM 47.06% 1-Year Est. Return

Royal Bank of Canada Toronto, Ontario, Canada $672B AUM 33.48% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Stratos Wealth Partners's FTXH Position: Q2 2026 in Review

Stratos Wealth Partners increased its First Trust Nasdaq Pharmaceuticals ETF (FTXH) stake by 9.3% in Q2 2026, buying an estimated $24.2K and bringing the position to 8,180 shares worth $312K. The position accounts for ﹤0.01% of the portfolio, ranked #1384.

Stratos Wealth Partners first reported a position in FTXH in Q3 2018 and has held it in 7 quarters since. 31 funds tracked by Wall St. Rank hold FTXH as of Q2 2026.

Stratos Wealth Partners held 8,180 shares of First Trust Nasdaq Pharmaceuticals ETF worth $312K as of Q2 2026.
Stratos Wealth Partners bought 696 First Trust Nasdaq Pharmaceuticals ETF shares in Q2 2026, an estimated $24.2K.
First Trust Nasdaq Pharmaceuticals ETF made up ﹤0.01% of Stratos Wealth Partners's portfolio in Q2 2026, its #1384 holding.
Stratos Wealth Partners first reported a position in First Trust Nasdaq Pharmaceuticals ETF in Q3 2018 and has held it in 7 quarters since.
31 funds tracked by Wall St. Rank held First Trust Nasdaq Pharmaceuticals ETF as of Q2 2026.

Based on Stratos Wealth Partners's 13F filing for Q2 2026, filed 11 Aug 2026.